Accelerate drug development           Proteomics technology           
 

   Intrinsic Bioprobes' mission is to improve the diagnosis
   and treatment of disease through the application of
   mass spectrometry based technologies.

News
Intrinsic Bioprobes enters into a $1.27M contract with the National Cancer Institute to develop Multiplex Mass Spectrometric Immunoassays for detection of low abundance cancer related proteins
Intrinsic Bioprobes develops novel mass spectrometry-based assay that reveals degradation and low levels of bioactive B-type Natriuretic Peptide (BNP) in patients with heart failure.
Events
IBI presented at the 2008 American Association for Cancer Research Annual meeting in San Diego, CA, April 12-16, 2008.
Publications
Detection of Endogenous B-Type Natriuretic Peptide at Very Low Concentrations in Patients with Heart Failure
Investigation of human protein variants and their frequency in the general population
 

© Copyright 2004-2009 by Intrinsic Bioprobes, Inc. All Rights Reserved.

Home | Sitemap | Directions | Literature